<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83658">
  <stage>Registered</stage>
  <submitdate>2/03/2009</submitdate>
  <approvaldate>15/05/2009</approvaldate>
  <actrnumber>ACTRN12609000273280</actrnumber>
  <trial_identification>
    <studytitle>Effect of Vitamin D2 and Vitamin D3 on serum 25-hydroxyvitamin D and parathyroid concentrations in healthy adult participants</studytitle>
    <scientifictitle>Effect of vitamin D2 and vitamin D3 supplementation on serum 25-hydroxyvitamin D and parathyroid concentrations in healthy adult participants</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Evaluating the relative potencies of equal molar doses of vitamin D2 and D3</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>vitamin D2 (ergocalciferol), vitamin D3 (cholecalciferol), both provided in a daily oral dose of 1000 IU, for a period of 6 months</interventions>
    <comparator>placebo, containing micro-crystalline cellulose, in a daily oral dose, for a period of 6 months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>serum 25-hydroxyvitamin D, measured in blood, by liquid chromatography mass spectrometry</outcome>
      <timepoint>baseline, week4, week8, week12, 6 months after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>parathyroid hormone, measured in blood by electrochemiluminescence immunoassay (ELECSYS)</outcome>
      <timepoint>baseline, week4, week8, week12, 6 months after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy males and females</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Body mass index greater than 27kg/m2
Chronic liver and kidney disease
Individuals taking medication, including anticonvulsants, glucocorticoids and barbiturates that might affect vitamin D metabolism
Individuals who are currently taking a vitamin D supplement</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>treatments will be coded by a third party (someone not involved in the study) and the code will be placed in a sealed envelope, which will not be opened until data collection, and analysis is completed</concealment>
    <sequence>A random list was generated using STATA software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>9/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago, Department of Human Nutrition</primarysponsorname>
    <primarysponsoraddress>University of Otago
PO Box 56
Dunedin
9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Otago Medical Research Foundation</fundingname>
      <fundingaddress>Department of Physiology
PO Box 913
Dunedin
9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Vitamin D is available in two forms, vitamin D2 and vitamin D3.  Vitamin D3 is synthesized in the human body, whereas vitamin D2 is commonly used in supplements.  It is not clear if the two forms have equivalent effects on serum 25-hydroxyvitamin D concentrations  the best measure of vitamin D status.  To date, results of studies have yielded conflicting results because of problems with study design including small number of participants, short study duration and confounding effects of seasonal changes in serum 25-hydroxyvitamin D concentrations.  We propose to evaluate the effects of daily doses of both vitamin D2 and vitamin D3 on serum changes in serum 25-hydroxyvitamin D and parathyroid concentrations over a sufficient period of time (4 mo).  As most clinical and public health recommendations do not distinguish between vitamin D2 and D3, the results of this study will provide a definitive answer to whether these 2 distinct forms should be regarded as equivalent and interchangeable.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Otago Ethics Committee</ethicname>
      <ethicaddress>University of Otago
PO Box 56
Dunedin
9054</ethicaddress>
      <ethicapprovaldate>19/12/2008</ethicapprovaldate>
      <hrec>08/187</hrec>
      <ethicsubmitdate>8/12/2008</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lisa Houghton</name>
      <address>PO Box 56 
Dunedin
9054</address>
      <phone>+64 3 479 7294</phone>
      <fax />
      <email>lisa.houghton@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa Houghton</name>
      <address>PO Box 56 
Dunedin
9054</address>
      <phone>+64 3 479 7294</phone>
      <fax />
      <email>lisa.houghton@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Meredith Rose</name>
      <address>PO Box 56 
Dunedin
9054</address>
      <phone>+64 3 479 5673</phone>
      <fax />
      <email>meredith.rose@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>